Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 217 participants.

Also called NCT01739400

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 217 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01739400
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Bulgaria, Chile, China, France, Germany, Greece, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Russia, Serbia, Spain, United Kingdom, Vietnam (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01739400. Allocation not applicable; no masking; primary purpose treatment. Start 2013-09-10 (actual); primary completion 2018-01-12 (actual). Results posted on 2019-04-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Acronym
MAESTRO-OL
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan 10 mg tablet, once daily.
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct01739400
Content hash
2fef3bda5957b8ffa52c1122dc5a89d8c002754fdd560f058d7052801edb9f6c